Braveheart Bio said Monday that the heart muscle therapy it licensed from China’s Jiangsu Hengrui Pharmaceuticals has succeeded in a mid-stage trial for the same condition in which Cytokinetics recently scored a

Send this story to anyone — or drop the embed into a blog post, Substack, Notion page. Every play sends rev-share back to Endpoints News.

𝕏 Post on X in Share on LinkedIn ✉ Email a friend

Heard via Storyflo

Get audio versions of every article you read.

Pick what matters — your audio curator gets you into your daily flo.

Join the listener waitlist

Braveheart Bio's Hengrui-licensed cardiac drug scores second clinical win · Storyflo